ACRBP (Acrosin Binding Protein)

The OY-TES-1 splice variant V5a is highly expressed in glioma, is associated with poor prognosis, and actively drives malignant behavior, indicating its potential utility as a prognostic biomarker and a candidate target for therapeutic intervention.

Drug sensitivity profiling highlighted differential therapeutic vulnerabilities between risk groups. This study established and validated a novel CTA-based prognostic tool for prognostic stratification and personalized treatment guidance in AML, bridging molecular insights with clinical applications.

This analysis aimed to explore the heterogeneity among ACRBP-expressing tumor cell populations and to investigate the correlation between ACRBP expression and immune molecule expression (including MHC and chemokines) alongside chemotherapy response. These insights furnish a theoretical framework supporting the future application of ACRBP in tumor immunotherapy and strategies to prevent immune escape.

These findings indicate that a medium supplemented with 5% KSR and 5% PRGF is ineffective for supporting complete in vitro spermatogenesis and may promote apoptosis. Importantly, these results provide insights into culture system design for future applications in fertility preservation strategies for prepubertal cancer patients at risk of gonadotoxicity.

The CCT4 up-regulation and PRAME mutations were correlated with a good prognosis for ovarian cancer, while higher levels of GAGE2A and CT45A1 mRNAs were correlated with a poor prognosis for ovarian cancer patients. Thus, GAGE2, CT45, CCT4, and PRAME cancer/testis antigens can be considered as potential prognostic markers for ovarian tumors, and GAGE2, CCT4, and PRAME were revealed to be correlated with the prognosis for ovarian cancer patients for the first time.

Conclusions Our study suggests that ACRBP functional polymorphisms (+26A/G) might possibly be associated with cancer and play a role in the pathogenesis of LC. Our findings indicate that rs11545745 could be a novel biomarker in LC patients diagnosis though detailed study on more LC patients need to be performed.

In summary, patients with postoperative recurrence and malignant transformation had poorer physical condition and higher degree of malignancy before surgery. Preoperative KPS score, duration of disease, surgical resection scope, postoperative treatment, OY-TES-1 mRNA, P53, MDM2, VEGF, and EGFR were the risk factors.

The offered vaccine, grounded on our in-silico investigation, may be considered for ovarian cancer immunotherapy. The online version contains supplementary material available at 10.1007/s10989-021-10294-w.

ACRBP expression was upregulated in OC tissues and induced humoral immune response in patients with OC, suggesting that ACRBP is a potential prognostic biomarker and a target of tumor immunotherapy for OC.

These data suggested that combined treatment with DAC, VPA and TSA may enhance the anti-tumor efficacy of ACRBP-specific T cells by upregulating ACRBP expression in HCC.

Zooming in on potential underlying mechanisms, we identified 7 CGAs, namely ACRBP, IL13RA2, TMEM108, GPATCH2, IMP3, TSGA10, ZNF165, the expression of which showed a, for some previously unrecognized, relationship with either aberrant influx, antigen-recognition and/or function of T cells in multiple tumor types. Here, we present the selection of these 7 CGAs, and provide an overview of reports on functional determinants that link this set of CGAs to T cell evasion, as well as the relevance of these CGAs to future immune therapeutic interventions.